Simon Quick Advisors LLC Purchases 3,627 Shares of Pfizer Inc. (NYSE:PFE)

Simon Quick Advisors LLC raised its position in shares of Pfizer Inc. (NYSE:PFE) by 15.5% in the first quarter, Holdings Channel reports. The fund owned 27,075 shares of the biopharmaceutical company’s stock after buying an additional 3,627 shares during the quarter. Simon Quick Advisors LLC’s holdings in Pfizer were worth $686,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Rialto Wealth Management LLC bought a new stake in Pfizer during the fourth quarter valued at about $26,000. Clarity Asset Management Inc. bought a new stake in Pfizer during the fourth quarter valued at about $27,000. Gould Capital LLC boosted its holdings in Pfizer by 97.2% during the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 493 shares during the period. Kohmann Bosshard Financial Services LLC bought a new stake in Pfizer during the fourth quarter valued at about $28,000. Finally, Bernard Wealth Management Corp. acquired a new position in shares of Pfizer during the fourth quarter valued at about $30,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Performance

NYSE:PFE opened at $24.85 on Friday. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $141.28 billion, a PE ratio of 17.62, a price-to-earnings-growth ratio of 0.64 and a beta of 0.57. The firm has a 50-day moving average price of $23.01 and a 200 day moving average price of $24.97.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The company’s quarterly revenue was down 7.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.82 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 6.92%. Pfizer’s dividend payout ratio is 124.64%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on PFE. Citigroup reaffirmed a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Cantor Fitzgerald began coverage on shares of Pfizer in a research report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Hsbc Global Res raised shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Finally, UBS Group upped their price objective on shares of Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research report on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.